A phase II study of intravenous 6-thioguanine (NSC-752) in advanced colorectal carcinoma.
Fifteen patients with advanced measurable colorectal carcinoma were treated with intravenous 6-thioguanine (6-TG) at a dosage of 55 mg/m2 for 5 consecutive days every 5 weeks. Only one patient had received prior adjuvant chemotherapy. No responses were detected, and eight patients had stable disease for a medium duration of three treatment cycles. Toxicity was tolerable. We conclude that 6-TG given by this dosage schedule is ineffective in treating metastatic colorectal carcinoma.
Rubin
J
J
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905.
Schutt
A J
AJ
Pitot
H C
HC
D000328:Adult; D000368:Aged; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage / Q000627:therapeutic use*
D013866:Thioguanine